Cargando…
Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
In a prior study, topiramate reduced heavy drinking among individuals who sought to reduce their drinking, with the effect moderated by a single nucleotide polymorphism (SNP; rs2832407) in GRIK1, which encodes the kainate GluK1 receptor subunit (Kranzler et al. 2014). The present study sought to rep...
Autores principales: | Kranzler, Henry R., Morris, Paige E., Pond, Timothy, Crist, Richard C., Kampman, Kyle M., Hartwell, Emily E., Lynch, Kevin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209023/ https://www.ncbi.nlm.nih.gov/pubmed/33568796 http://dx.doi.org/10.1038/s41386-020-00945-9 |
Ejemplares similares
-
Correction to: Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
por: Kranzler, Henry R., et al.
Publicado: (2021) -
Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial
por: Wetherill, Reagan R., et al.
Publicado: (2021) -
Survey of Addiction Specialists’ Use of Medications to Treat Alcohol Use Disorder
por: Ehrie, Jarrod, et al.
Publicado: (2020) -
A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020) -
Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration
por: Del Re, A C, et al.
Publicado: (2013)